



# TRIAMVIRGI

Corticosteroids

**Recommended treatment of:**

Systemic corticosteroid therapy of morbid conditions such as allergic syndromes, dermatosis, general rheumatoid arthritis, and other affections of the connective tissues.

**Dosage & pack size:**

80 mg/2ml - Box of 5 ampoules

**Registered for use in:**

Italy, Vietnam

*For further detailed description, see back side.*

**Route of administration:**

i.m; intra-articular; intrabursal

**Active principle:**

Triamcinolone Acetonide





**Recommended treatment of:**

Systemic corticosteroid therapy of morbid conditions such as allergic syndromes (control of severe or incapacitating allergic conditions when conventional treatment is not feasible), dermatosis, general rheumatoid arthritis, and other affections of the connective tissues.

The i.m. route is particularly useful when oral corticosteroid therapy is not feasible.

Triamvirgi is also given by intra-articular or intrabursal route or directly in the tendon sheaths and cystic tendon formations. These routes of administration allow to perform a valid short-term local treatment of pain, swelling, and articular rigidity due to traumatic or

rheumatoid arthritis, osteoarthritis, synovitis, bursitis and tenositis.

In the treatment of the general arthritis diseases, Triamvirgi given by intra-articular injection is intended to support other conventional therapeutic measures. Limited morbid processes such as traumatic arthritis or bursitis represent typical indications for instituting intra-articular therapy.

